Deceased 36 (12.8%) | Alive 253 (87.2%) | p value | |
---|---|---|---|
Age (years) | 72.8 ± 9.0 | 61.9 ± 11.3 | < 0.0001 |
Sex (n; %) | F 14 (38.9%) M 22 (61.1%) | F 117 (46.2%) M 136 (53.8%) | ns |
BMI (kg/m2) | 30.0 ± 5.8 | 30.6 ± 6.0 | ns |
SBP (mmHg) | 145.6 ± 19.8 | 140.3 ± 19.7 | ns |
DBP (mmHg) | 84.8 ± 11.3 | 82.8 ± 11.0 | ns |
Fasting glucose (mg/dL) | 156 ± 50 | 158 ± 59 | ns |
Hb1Ac (%) | 7.9 ± 1.3 | 7.6 ± 1.8 | ns |
Patients with HbA1c > 8% (n; %) | 15; 45.5 | 58; 25.5 | 0.0174 |
Total cholesterol (mg/dL) | 196 ± 40 | 203 ± 44 | ns |
HDL-cholesterol (mg/dL) | 51 ± 14 | 48 ± 16 | ns |
LDL-cholesterol (mg/dL) | 122 ± 53 | 122 ± 41 | ns |
Triglycerides (mg/dL) | 136 ± 75 | 173 ± 108 | ns |
ALT (IU/L) | 25 ± 12 | 33 ± 23 | ns |
AST (IU/L) | 21 ± 7 | 25 ± 13 | ns |
γGT (IU/L) | 44 ± 28 | 51 ± 62 | ns |
Serum creatinine (mg/dL) | 1.06 ± 0.6 | 0.93 ± 0.37 | ns |
eGFR CKD-EPI (mL/min/1.73 m2) | 70.6 ± 19.2 | 81.0 ± 20.0 | 0.0256 |
eGFR < 60 mL/min/1.73 m2 (n; %) | 8; 22.2 | 30; 11.9 | ns |
Uric acid (mg/dL) | 4.9 ± 1.1 | 6.2 ± 0.2 | 0.0291 |
Diabetic retinopathy (n; %) | 1; 2.8 | 6; 2.4 | ns |
Previous CV disease (n; %) | 6; 16.7 | 38; 15.0 | ns |
Heart failure (n; %) | 4; 11.1 | 15; 5.9 | ns |
Atrial fibrillation (n; %) | 6; 16.7 | 17; 6.7 | 0.0067 |
Any cancer (n; %) | 10; 27.8 | 40; 15.8 | ns |
No treatment (n; %) | 16; 44.4 | 139; 54.9 | ns |
Metformin (n; %) | 12; 33.3 | 72; 28.5 | ns |
Secretagogues (n; %) | 8; 22.2 | 42; 16.6 | ns |
Anti-hypertensive treatment (n; %) | 23; 63.9 | 156; 61.6 | ns |
Statins (n; %) | 14; 38.9 | 74; 29.2 | ns |